Results 41 to 50 of about 33,732 (139)

Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis

Swiss Medical Weekly, 2023
AIMS OF THE STUDY: Remdesivir has shown benefits against COVID-19. However, it remains unclear whether, to what extent, and among whom remdesivir can reduce COVID-19-related mortality. We explored whether the treatment response to remdesivir differed by
Janne Estill, Plamenna Venkova-Marchevska, Huldrych F. Günthard, Sara Botero-Mesa, Amaury Thiabaud, Maroussia Roelens, Laure Vancauwenberghe, Lauro Damonti, Ulrich Heininger, Anne Iten, Peter W. Schreiber, Rami Sommerstein, Sarah Tschudin-Sutter, Nicolas Troillet, Danielle Vuichard-Gysin, Andreas Widmer, Torsten Hothorn, Olivia Keiser   +17 more
doaj   +1 more source

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

Remdesivir administration for Japanese COVID-19 patients undergoing maintenance hemodialysis: a retrospective observation with six case reports

Renal Replacement Therapy, 2022
Background The mortality rate of novel coronaviral disease (COVID-19) patients undergoing dialysis is considerably higher than that of patients with normal kidney function.
Jun Ito, Moritsugu Kimura, Tomoyuki Toya, Konomi Isozumi, Atsuro Kawaji, Yudai Isozaki, Masafumi Fukagawa   +6 more
doaj   +1 more source

Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

Journal of Infection and Public Health, 2021
The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries, including Saudi Arabia, since 2020. The generic structure of remdesivir was first disclosed in 2009.
Mohd. Imran, Ahmed Subeh Alshrari, Syed Mohammed Basheeruddin Asdaq, Abida   +3 more
doaj   +1 more source

Successful in vitro propagation of feline coronavirus from clinically diagnosed feline infectious peritonitis cases using Vero cells: A potential model for future research

Veterinary Record Open, Volume 13, Issue 1, June 2026.
Abstract Background Feline coronavirus (FCoV) causes inapparent to progressive fatal feline infectious peritonitis (FIP) in domestic and wild cats, which affects multiple‐organ systems. Methods We investigated three clinically sick cats using different laboratory and molecular tests to diagnose and confirm FCoV and propagate the virus in Vero cell ...
Eaftekhar Ahmed Rana, Mahfuza Akther, Susan Beetson, Subir Sarker, Gabriele Rossi, Jasim M. Uddin   +5 more
wiley   +1 more source

A Case of Cytokine Release Syndrome Induced by Avelumab and Axitinib Combination Therapy for Metastatic Renal Cell Carcinoma

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Cytokine release syndrome (CRS) is a rare immune‐related adverse event of immune checkpoint inhibitors (ICIs). At present, its association with avelumab–axitinib therapy for renal cell carcinoma (RCC) has yet to be reported. Differentiating early CRS from an infusion‐related reaction (IRR) is clinically challenging, particularly ...
Rio Shibata, Taku Mochizuki, Takashi Kawahara, Tomoharu Morikawa, Hirokazu Kiuchi, Takahiro Hanai, Jun‐ichi Teranishi, Kimio Chiba   +7 more
wiley   +1 more source

Temporal Trends in Physician Burnout During and After the COVID‐19 Pandemic in Japan: A Repeated Cross‐Sectional Study

Journal of General and Family Medicine, Volume 27, Issue 2, March 2026.
ABSTRACT Background To examine how burnout among Japanese internists and primary care physicians evolved from the onset of the coronavirus disease‐2019 (COVID‐19) pandemic to the post‐pandemic period. Methods We reanalyzed data from five web‐based surveys of members of the American College of Physicians—Japan Chapter between January 2020 and April 2024.
Akira Kuriyama, Kiyoshi Shikino
wiley   +1 more source

Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models

Scientific Reports, 2021
Human coronavirus NL63 (HCoV-NL63) mainly affects young children and immunocompromised patients, causing morbidity and mortality in a subset of patients.
Yining Wang, Pengfei Li, Sajjan Rajpoot, Uzma Saqib, Peifa Yu, Yunlong Li, Yang Li, Zhongren Ma, Mirza S. Baig, Qiuwei Pan   +9 more
doaj   +1 more source

Protective Effect of Remdesivir Against Pulmonary Fibrosis in Mice

Frontiers in Pharmacology, 2021
Pulmonary fibrosis is a known sequela of severe or persistent lung damage. Existing clinical, imaging and autopsy studies have shown that the lungs exhibit a pathological pulmonary fibrosis phenotype after infection with coronaviruses, including severe ...
Xiaohe Li, Xiaohe Li, Rui Liu, Rui Liu, Yunyao Cui, Yunyao Cui, Jingjing Liang, Jingjing Liang, Zhun Bi, Shimeng Li, Shimeng Li, Yang Miao, Liang Zhang, Xiaoping Li, Honggang Zhou, Honggang Zhou, Cheng Yang, Cheng Yang   +17 more
doaj   +1 more source

Are Tetrapleura tetraptera Phytochemicals Druggable Against SARS‐CoV‐2 Papain‐Like Protein? A Computational Approach

New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.
SARS‐CoV2 Omicron and its substrains are still a critical global health issue and extremely contagious, even with widespread vaccination efforts. Hospitalizations and mortality rates linked to these variants are still prevalent. Current therapeutic options face challenges, including low effectiveness, suboptimal pharmacokinetics, and drug resistance ...
Frank Eric Tatsing Foka, Hazel Tumelo Mufhandu   +1 more
wiley   +1 more source